With GDP growth at 4.6% for 2017, pharma market growth of 4.2%, 38 million people, and a strategic location in the center of Europe, Poland has solid foundations for success in healthcare and the life sciences. The situation is improving for both generics companies and innovators and there are plans to increase public health expenditure to 6% by 2025.

Multinational companies are flocking to Poland to establish manufacturing sites, global shared service centers and clinical trials facilities. Domestic generics players continue to perform well – with some now possessing the means and expertise to move into biologics. This report touches on all the main themes currently at play in the industry through the exclusive insights of some of its major players.